Supply officials warned that the U.S. would face a COVID-19 drug shortage by summer as White House COVID-19 coordinator Ashish Jha, MD, called the current pool of funds “the bare minimum” after Congress slashed the proposed budget from $25.5 billion to $10 billion in May.
About half of the rerouted funds are marked for 10 million Paxlovid courses, according to the Times. Paxlovid is the nation’s most prescribed at-home COVID-19 treatment and was inaccessible to 26 million people at the beginning of 2022.
With the new plan, HHS can’t afford to support normal production levels for COVID-19 tests and PPE, leaving hundreds of stateside manufacturing jobs in jeopardy, according to the Times.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.